Apellis Pharma DEF 14A: Executive Compensation Details
Ticker: APLS · Form: DEF 14A · Filed: Apr 23, 2025 · CIK: 1492422
Sentiment: neutral
Topics: executive-compensation, equity-awards, sec-filing
Related Tickers: APLS
TL;DR
Apellis Pharma dropped its DEF 14A - exec comp details for 2020-2023 are out.
AI Summary
Apellis Pharmaceuticals, Inc. filed a DEF 14A on April 23, 2025, detailing executive compensation and equity awards for the fiscal years ending December 31, 2020, through 2023. The filing includes information on year-end fair values of equity awards granted and outstanding, as well as changes in fair value for awards vesting in covered years. Specific dollar amounts and dates related to these awards are presented within the compensation tables.
Why It Matters
This filing provides transparency into how Apellis Pharmaceuticals compensates its top executives, which can influence investor perception and employee morale.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of executive compensation and does not present new financial risks.
Key Players & Entities
- Apellis Pharmaceuticals, Inc. (company) — Filer of the DEF 14A
- 20250423 (date) — Filing date of the DEF 14A
- 2020-12-31 (date) — Fiscal year end date referenced in the filing
- 2023-12-31 (date) — Fiscal year end date referenced in the filing
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose of this DEF 14A filing is to provide detailed information regarding the compensation of Apellis Pharmaceuticals, Inc.'s named executive officers and directors.
What fiscal years are covered by the compensation data in this filing?
The compensation data in this filing covers the fiscal years ending December 31, 2020, 2021, 2022, and 2023.
What type of compensation elements are detailed for the executives?
The filing details various compensation elements including equity awards, such as year-end fair values of equity awards granted and outstanding, and changes in fair value of equity awards.
Where is Apellis Pharmaceuticals, Inc. headquartered?
Apellis Pharmaceuticals, Inc. is headquartered at 100 Fifth Avenue, Waltham, MA 02451.
What is the Standard Industrial Classification (SIC) code for Apellis Pharmaceuticals, Inc.?
The Standard Industrial Classification (SIC) code for Apellis Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 23, 2025 regarding Apellis Pharmaceuticals, Inc. (APLS).